Trial Profile
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ALCYONE
- Sponsors Genmab; Janssen Biotech; Janssen Research & Development; Janssen-Cilag
- 12 Feb 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 03 Feb 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 12 Dec 2023 Results of a sub-group pooled analysis assessing progression-free survival by measurable residual disease and cytogenetic risk status from OCTANS and ALCYONE presented at the 65th American Society of Hematology Annual Meeting and Exposition